Mucosal 5‐aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis

BACKGROUND: 5‐aminosalicylic acid (5‐ASA) is the first‐line therapy for ulcerative colitis (UC). 5‐ASA acts locally in the colonic mucosa by numerous proposed mechanisms, and is metabolised by N‐acetyltransferase (NAT). Large variations in mucosal 5‐ASA concentrations have been reported, but the und...

Descripción completa

Detalles Bibliográficos
Autores principales: Olaisen, Maya, Spigset, Olav, Flatberg, Arnar, Granlund, Atle van Beelen, Brede, Wenche Rødseth, Albrektsen, Grethe, Røyset, Elin Synnøve, Gilde, Bodil, Sandvik, Arne Kristian, Martinsen, Tom Christian, Fossmark, Reidar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
5‐aminosalicylic Acid and the Mucosal Microbiome in Ulcerative Colitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593792/
https://www.ncbi.nlm.nih.gov/pubmed/30895635
http://dx.doi.org/10.1111/apt.15227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593792/
https://www.ncbi.nlm.nih.gov/pubmed/30895635
http://dx.doi.org/10.1111/apt.15227

Ejemplares similares